ReviewGene therapy2003
Vectors for the treatment of autoimmune disease.
Review in Gene therapy, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Engineered exosomes: a promising drug delivery platform with therapeutic potential.Frontiers in molecular biosciences · 2025Review
- Exosomes and their derivatives as biomarkers and therapeutic delivery agents for cardiovascular diseases: Situations and challenges.Journal of translational internal medicine · 2023Article
- LncRNAInternational journal of molecular sciences · 2021Review
- Long noncoding RNAs and tumorigenesis: genetic associations, molecular mechanisms, and therapeutic strategies.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Review
- Gene therapy, early promises, subsequent problems, and recent breakthroughs.Advanced pharmaceutical bulletin · 2013Article
- Packaging HIV- or FIV-based lentivector expression constructs and transduction of VSV-G pseudotyped viral particles.Journal of visualized experiments : JoVE · 2012Article
- Expression Cloning of Recombinant Escherichia coli lacZ Genes Encoding Cytoplasmic and Nuclear β-galactosidase Variants.Iranian journal of basic medical sciences · 2011Article
- Adeno-associated virus serotype 2 induces cell-mediated immune responses directed against multiple epitopes of the capsid protein VP1.The Journal of general virology · 2009Article
- The effects of N-terminal insertion into VSV-G of an scFv peptide.Virology journal · 2006Article
- Treatment of human disease by adeno-associated viral gene transfer.Human genetics · 2006Review
- Gene therapy for arthritis--where do we stand?Arthritis research & therapy · 2005Article
- Prevention of experimental autoimmune encephalomyelitis in DA rats by grafting primary skin fibroblasts engineered to express transforming growth factor-beta1.Clinical and experimental immunology · 2004Article
- Inhibition of established collagen-induced arthritis with a tumour necrosis factor-alpha inhibitor expressed from a self-contained doxycycline regulated plasmid.Arthritis research & therapy · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gene therapy has been applied in a variety of experimental models of autoimmunity with some success. In this article, we outline recent developments in gene therapy vectors, discuss advantages and disadvantages of each, and highlight their recent applications in autoimmune models. We also consider progress in vector targeting and components for regulating transgene expression, which will both improve gene therapy safety and empower gene therapy to fullfil its potential as a therapeutic modality. In conclusion, we consider candidate vectors that satisfy requirements for application in the principal therapeutic strategies in which gene therapy will be applied to autoimmune conditions.
Indexed as
Identifiers
12732876What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.